Israel requires updated labelling for topiramate and fluoroquinolones due to safety concerns
This article was originally published in SRA
The Pharmaceutical Administration of the Israeli Ministry of Health has issued a circular requiring an immediate update of the labelling of topiramate tablets, namely, the physician prescribing information and the patient information leaflet, approved for marketing in Israel. It has also issued a separate circular requiring local manufacturers and importers of medicinal products to update immediately the labelling of all fluoroquinolone products. Both circulars were issued on 13 March.